Legend Biotech: CARVYKTI™ to Treat Multiple Myeloma

Legend Biotech: CARVYKTI™ to Treat Multiple Myeloma

Legend Biotech Corporation (Legend Biotech) announced that the U.S. Food and Drug Administration (FDA) has approved its first product, CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), to treat adult patients with relapsed or refractory multiple myeloma (RRMM) who...